Standard Contracts
RESEARCH AND EXCLUSIVE LICENSE OPTION AGREEMENTResearch and Exclusive License Option Agreement • July 6th, 2011 • Biotime Inc • Biological products, (no disgnostic substances)
THIS AGREEMENT is made on October 7, 2010 effective subject to the closing of the investment round envisaged in the Share Purchase Agreement (as defined herein) (the date being of such closing being referred to herein as the "Effective Date") between
AMENDMENT NO. 1 TO RESEARCH AND EXCLUSIVE LICENSE OPTION AGREEMENTResearch and Exclusive License Option Agreement • January 20th, 2011 • Rexahn Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Amendment No. 1 to the Research and Exclusive License Option Agreement, dated as of January 19, 2011 (this “Amendment”), is made by and between Rexahn Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware (the “Company”), and Teva Pharmaceutical Industries Limited, a limited liability company organized and existing under the laws of Israel (the “Purchaser”). Any capitalized term not defined herein shall have the meaning for such term specified in the RELO Agreement (as defined below).
RESEARCH AND EXCLUSIVE LICENSE OPTION AGREEMENTResearch and Exclusive License Option Agreement • June 30th, 2009 • Rexahn Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Rexahn Pharmaceuticals, Inc., a company incorporated under the laws of the State of Delaware, United States of America, located at 9620 Medical Center Drive, Rockville, Maryland 20850 (“Rexahn”).
AMENDMENT NO. 2 TO RESEARCH AND EXCLUSIVE LICENSE OPTION AGREEMENTResearch and Exclusive License Option Agreement • November 27th, 2012 • Rexahn Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Amendment No. 2 to the Research and Exclusive License Option Agreement, dated as of November 27, 2012 (this “Amendment”), is made by and between Rexahn Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware (“Rexahn”), and Teva Pharmaceutical Industries Limited, a limited liability company organized and existing under the laws of Israel (“Teva”). Any capitalized term not defined herein shall have the meaning for such term specified in the RELO Agreement (as defined below).
RESEARCH AND EXCLUSIVE LICENSE OPTION AGREEMENTResearch and Exclusive License Option Agreement • September 21st, 2009 • Rexahn Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Teva Pharmaceutical Industries Limited, a limited liability company incorporated under the laws of Israel, located at 5 Basel Street, Petach Tiqva 49131, Israel (“Teva”);
RESEARCH AND EXCLUSIVE LICENSE OPTION AGREEMENTResearch and Exclusive License Option Agreement • March 15th, 2011 • Biotime Inc • Biological products, (no disgnostic substances)
THIS AGREEMENT is made on October 7, 2010 effective subject to the closing of the investment round envisaged in the Share Purchase Agreement (as defined herein) (the date being of such closing being referred to herein as the "Effective Date") between
